The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Halimatoz

20 milligram(s) Solution for injection in pre-filled syringe

Sandoz GmbHEU/1/18/1288/007

Main Information

Trade NameHalimatoz
Active SubstancesAdalimumab
Strength20 milligram(s)
Dosage FormSolution for injection in pre-filled syringe
Licence HolderSandoz GmbH
Licence NumberEU/1/18/1288/007

Group Information

ATC CodeL04AB04 adalimumab

Status

Authorised/WithdrawnAuthorised
Licence Issued27/03/2020
Legal status*** AWAITING VALUE ***
Supply Status
Advertising Status*** AWAITING VALUE ***
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back